325P A phase II, open-label, single-center study of QL1706 plus platinum doublet chemotherapy with or without bevacizumab as first-line treatment in patients with advanced NSCLC: Data from EGFR wild-type cohort

Abstract

Immunotherapy plus platinum doublet chemotherapy (chemo) as first-line therapy has shown survival benefit in patients (pts) with advanced NSCLC not harboring oncogenic driver alterations. QL1706, a novel dual immune checkpoint blockade containing a mixture of anti-PD1 IgG4 and anti-CTLA4 IgG1 antibodies, showed promising antitumor efficacy in advanced solid tumors including NSCLC in a phase (Ph) I trial. Here we report the efficacy and safety results from the EGFR wild-type (WT) cohort of an ongoing Ph II study of QL1706 plus chemo±bevacizumab in pts with advanced NSCLC.